Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

argenx Receives Approval Of VYVGART In Japan For Adults With Primary Immune Thrombocytopenia

Author: Benzinga Newsdesk | March 26, 2024 03:15am

VYVGART® now approved in Japan for both generalized myasthenia gravis and primary immune thrombocytopenia (ITP)

Regulatory decision in Japan represents first global approval for VYVGART in ITP

Posted In: ARGX